万达生物制药宣布正式启动名为"Thetis研究"的临床试验，该试验旨在评估其创新药物Nereus™对GLP-1受体激动剂引发的呕吐症状的预防效果。这项研究将针对使用GLP-1受体激动剂治疗时出现胃肠道不良反应的患者群体，探索Nereus™在控制药物相关性呕吐方面的潜在疗效。
作为针对新型降糖药物副作用的前瞻性研究，该试验设计将采用多中心、随机对照模式，重点关注Nereus™对患者用药耐受性和生活质量的改善作用。GLP-1受体激动剂虽然在全球糖尿病和肥胖症治疗领域取得显著成效，但其引发的恶心呕吐等副作用始终是影响患者用药依从性的重要障碍。
此次临床试验的启动，标志着万达生物制药在消化系统副作用管理领域迈出关键一步。若试验结果积极，Nereus™有望成为首款专门针对GLP-1类药物相关呕吐症状的预防性疗法，为全球数百万相关患者提供新的解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.